Novartis, Inclisiran (Leqvio): twice-yearly siRNA against PCSK9 for LDL-cholesterol lowering (sponsor’s own account)

Cited by name. No followable URL — the bibliographic record is the citation.

Authors. Novartis

Venue. (sponsor’s own account)

How the Institute flags it

established 1 time

Cited on 1 page

• RNA Medicines